Document is current
Any future updates will be listed below
-
Authors
McAdam, Jordan https://orcid.org/0000-0001-9905-6001
Richard, Stephanie A. https://orcid.org/0000-0002-0530-384X
Olsen, Cara H. https://orcid.org/0000-0002-2734-4511
Byrne, Celia https://orcid.org/0000-0001-8289-4252
Clausen, Shawn
Michel, Amber
Agan, Brian K. https://orcid.org/0000-0002-5114-1669
O’Connell, Robert
Burgess, Timothy H.
Tribble, David R. https://orcid.org/0000-0003-3077-9505
Pollett, Simon
Mancuso, James D. https://orcid.org/0000-0002-0717-8202
Rusiecki, Jennifer A. https://orcid.org/0000-0003-3881-8695
-
Funding
Funding for this research was provided by:
Defense Health Agency (HU00012020067)
National Institute of Allergy and Infectious Disease (HU00011920111)
National Institute of Allergy and Infectious Diseases at the National Institutes of Health (Y1-AI-5072)
- License Information
-
More Information
Article History
Received: 15 October 2024
Revised: 26 December 2024
Accepted: 18 February 2025
First Online: 21 March 2025
Declarations
:
: This study was approved by the Uniformed Services University of the Health Sciences (USUHS) Institutional Review Board (IRB) under protocol IDCRP-085 [ ]; all participants or their legally authorized representative provided informed consent to participate.
: SP, THB, and DRT report that the Uniformed Services University (USU) Infectious Diseases Clinical Research Program (IDCRP), a US Department of Defense institution, and the Henry M. Jackson Foundation (HJF) were funded under a Cooperative Research and Development Agreement to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial sponsored by AstraZeneca. The HJF, in support of the USU IDCRP, was funded by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense to augment the conduct of an unrelated phase III vaccine trial sponsored by AstraZeneca. Both trials were part of the US Government COVID-19 response. Neither is related to the work presented here. The other co-authors have nothing to declare.
: All opinions expressed here are the authors’ and do not necessarily reflect the policies and official views of the Uniformed Services University of the Health Sciences or the Department of Defense. The contents of this publication are the sole responsibility of the author(s) and do not necessarily reflect the views, opinions, or policies of Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), Uniformed Services University of the Health Sciences (USUHS), the Department of Defense (DoD), the Departments of the Army, Navy, or Air Force, or the Defense Health Agency. Mention of trade names, commercial products, or organizations does not imply endorsement by the US Government.CHO, SC, CB, RO, THB, DRT, JDM and JAR are service members or employees of the US Government. This work was prepared as part of their official duties. Title 17 U.S.C. §105 provides that “Copyright protection under this title is not available for any work of the United States Government.” Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or employee of the US Government as part of that person’s official duties.
: Brooke Army Medical Center, Fort Sam Houston, TX: T. MerrittNaval Medical Center San Diego, San Diego, CA: C. Berjohn, Ryan C. Maves.Uniformed Services University of the Health Sciences, Bethesda, MD: M. FritschlanskiUnited States Air Force School of Aerospace Medicine, Dayton, OH: R. Chapleau
